Amir T. Fathi, MD

Amir T. Fathi, MDProgram Director, Center for Leukemia
Massachusetts General Hospital Cancer Center
Assistant Professor in Medicine
Harvard Medical School
Boston, Massachusetts


Dr. Amir Fathi graduated summa cum laude from Yale University with a BS degree in molecular, cellular, and developmental biology. He went on to receive his medical degree with honors at the Yale School of Medicine. He also has a master’s degree in epidemiology from Harvard School of Public Health. Dr. Fathi completed his residency training in internal medicine at Massachusetts General Hospital (MGH), and fellowships in both hematology and medical oncology at Johns Hopkins Hospital. He is the Program Director of the Center for Leukemia at the Massachusetts General Hospital Cancer Center; he is also an Assistant Professor in Medicine at Harvard Medical School.

Dr. Fathi has presented at national meetings of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH), spoken at national academic and educational meetings, and has served on national committees that establish guidelines for the management of acute and chronic leukemias. As faculty at the MGH Cancer Center and Harvard Medical School, Dr. Fathi provides clinical care, supervises trainees, administers a busy clinic, and as the director of clinical research in leukemia, is the lead investigator on numerous clinical trials investigating novel treatments in acute leukemias.

Outcomes for patients with acute myeloid leukemia (AML) continue to be poor despite incremental advances in treatment and supportive care over the last 30 years. Although most patients respond to initial treatment, the majority eventually relapse and many succumb to their disease. Therefore, new and innovative approaches are desperately needed to significantly improve outcomes. As a clinician-scientist with a deep interest in developing novel therapies for AML, Dr. Fathi endeavors to provide outstanding clinical care, teaching, and mentoring, while also conducting translational projects, retrospective research, and clinical trials, with the overarching goal improving the health and outcomes of patients with bone marrow malignancies.

Last modified: November 15, 2018

Authored Items